Renalytix Plc

As of September 30, 2024, Renalytix Plc has 189.93M shares outstanding.

These figures are as of September 30, 2024. The price-to-sales ratio is 4.52, and the price-to-book ratio stands at -0.05.

These figures are as of September 30, 2024. The EV/Sales ratio of 7.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of September 30, 2024, Renalytix Plc maintains a current ratio of 0.24, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -235.69, reflecting losses generated across the asset base.

Over the twelve months ended September 30, 2024, Renalytix Plc posted a gross margin of 13.90, reflecting its pricing power and cost economics. The operating margin of -1,051.83 and net profit margin of -1,219.26 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2024. Free cash flow yield is negative at -229.93: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -106.44, meaning Renalytix Plc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of September 30, 2024, Renalytix Plc has an Altman Z-Score of -81.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.